

CHIASMA, INC  
Form 8-K  
April 08, 2019

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of The Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported): April 8, 2019**

**Chiasma, Inc.**

**(Exact name of registrant as specified in its charter)**

**DELAWARE**  
**(State or other jurisdiction**

**of incorporation)**

**001-37500**  
**(Commission**

**File Number)**

**76-0722250**  
**(I.R.S. Employer**

**Identification No.)**

**460 Totten Pond Rd, Suite 530**

**Waltham, MA**

**02451**

**(Address of principal executive offices)**

**(Zip Code)**

**Registrant's telephone number, including area code (617) 928-5300**

**Not Applicable**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 2.02. Results of Operations and Financial Condition.**

Mark J. Fitzpatrick, President and Chief Executive Officer, and William Ludlam, Senior VP, Clinical Development and Medical Affairs, of Chiasma, Inc. (the Company), will present at the HC Wainwright & Co. Global Life Sciences Conference in London, UK on April 8, 2019 at 9:10 a.m. ET. A copy of the presentation slide deck, which includes updated financial information and cash guidance, is being furnished as Exhibit 99.1 to this Report on Form 8-K.

**Item 7.01. Regulation FD Disclosure.**

Reference is made to, and there is hereby incorporated by reference into this Item 7.01, the information set forth above under Item 2.02. Results of Operations and Financial Condition.

The information in this Report on Form 8-K is intended to be furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

**Exhibit**

<b>No.</b>	<b>Description</b>
99.1	<u>Slide Presentation of Chiasma, Inc. dated April 2019, furnished hereto.</u>

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 8, 2019

**Chiasma, Inc.**

By: /s/ Mark J. Fitzpatrick  
Mark J. Fitzpatrick  
President, Chief Executive Officer, and Director